Financial Performance - For the nine months ended September 30, 2021, the group recorded revenue of approximately RMB 55,829,000, an increase of about 8.5% compared to the same period in 2020[5]. - For the same period, the group reported a profit before tax of approximately RMB 31,059,000, a decrease of about 16.1% compared to the prior year[6]. - Basic earnings per share for the nine months were approximately RMB 2.59 cents, down about 21.5% from the same period in 2020[7]. - The gross profit for the nine months was approximately RMB 44,064,000, compared to RMB 38,622,000 in the same period last year[11]. - The total comprehensive income for the nine months was RMB 25,808,000, compared to RMB 32,799,000 in the same period last year[11]. - Total revenue for the period increased by 8.5% compared to the same period in 2020, with total revenue for the three months ended September 30, 2021, decreasing by 18.00% compared to the same period in 2020[20]. - Basic earnings per share were approximately RMB 25,808,000, compared to RMB 32,799,000 for the same period in 2020, with a weighted average number of ordinary shares of approximately 995,351,660[23]. - The group achieved a pre-tax profit of approximately RMB 31,059,000, down from RMB 37,023,000 in the same period last year, with net profit approximately RMB 25,808,000 compared to RMB 32,799,000 last year, primarily due to the sale of three wholly-owned subsidiaries which generated a transfer gain of RMB 10,224,000 last year[34]. Dividends - The board of directors proposed not to declare any dividend for the nine months ended September 30, 2021[8]. - The company has not recommended any dividend payments for the period[27]. - The board does not recommend the distribution of dividends for the nine months ended September 30, 2021, consistent with the previous year[36]. Operating Expenses - The operating expenses for the nine months were RMB 31,070,000, down from RMB 37,061,000 in the previous year[11]. - Administrative expenses rose by 10.86% compared to the same period in 2020, amounting to RMB 2,728,000 for the three months ended September 30, 2021[21]. Business Strategy and Development - The group aims to become a comprehensive service provider under an internet architecture in the healthcare sector[16]. - The company has established a biobank testing laboratory to support clinical research, particularly for antiviral drug studies[29]. - The company launched two new business models: "RWS-Therapy" and "D-CRCO," aimed at redefining research-based treatment and commercialization through big data[30]. - The company has formed partnerships with top medical institutions in cities like Beijing, Shanghai, and Guangzhou to enhance digital healthcare services[30]. - The company is exploring a comprehensive digital healthcare service model that integrates research, rehabilitation, and medical tourism[31]. - The group is enhancing its marketing capabilities and expanding its market network, focusing on a value chain business model in the local market with its sub-brands[35]. - The board will review and evaluate potential projects or investments to enhance business performance and shareholder returns[35]. Financial Position and Investments - The group has not made any significant investments during the reporting period, similar to the situation as of December 31, 2020[37]. - As of September 30, 2021, the group had no unrecorded contingent liabilities, maintaining the same status as of December 31, 2020[38]. - The company has not disclosed any significant future investment or capital asset plans beyond what has been reported[39]. Shareholding Structure - Winsland Agents Limited holds 349,368,873 shares, representing 35.10% of the company's equity[55]. - Venturepharm Holdings Inc. has a beneficial ownership of 149,432,583 shares, accounting for 15.01% of the equity[55]. - Bright Excel Assets Limited, a wholly-owned subsidiary of Venturepharm Holdings Inc., holds 91,915,181 shares, which is 9.23% of the equity[57]. - The company has a controlled corporation interest of 241,347,764 shares, which is 24.25% of the equity[55]. Governance and Compliance - The company has not appointed a CEO, with daily management handled by executive directors and senior management[60]. - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited consolidated results for the period[62]. - The company maintains sufficient public float as of the report date[64]. - The company has complied with the GEM Listing Rules regarding securities trading standards during the reporting period[61]. - The board emphasizes high-quality governance and transparency to shareholders[60]. Miscellaneous - The group has not recognized any revenue from contract clinical research services during the period[20]. - There were no purchases, sales, or redemptions of the company's listed shares by the company or any of its subsidiaries during the nine months ended September 30, 2021[42]. - The report was published on November 11, 2021, and will be available on the GEM website for seven days[66].

Financial Performance - For the six months ended June 30, 2021, the group recorded revenue of approximately RMB 48,093,000, an increase of about 14.44% compared to the same period in 2020[4] - The group reported a profit before tax of approximately RMB 27,977,000 for the six months ended June 30, 2021, representing an increase of approximately 9.56% year-on-year[5] - Basic earnings per share for the six months ended June 30, 2021, were approximately RMB 2.33 cents, up about 4.95% from the same period in 2020[6] - The group’s net profit for the six months ended June 30, 2021, was RMB 23,188,000, compared to RMB 22,047,000 for the same period in 2020[10] - The total revenue for the six months ended June 30, 2021, increased by 14.44% compared to the same period in 2020, with PMS revenue growing approximately 16.80%[24] - The net profit attributable to the owners of the company for the period was approximately RMB 23,188,000, compared to RMB 22,047,000 in 2020[27] Assets and Liabilities - The group’s total assets less current liabilities as of June 30, 2021, amounted to RMB 142,435,000, compared to RMB 118,675,000 as of December 31, 2020[12] - The group’s cash and cash equivalents at the end of the period were RMB 11,582,000, down from RMB 16,193,000 at the beginning of the period[14] - The net cash used in operating activities for the six months ended June 30, 2021, was RMB (2,344,000), compared to RMB 3,113,000 for the same period in 2020[14] - Trade receivables increased to RMB 116,367,000 as of June 30, 2021, from RMB 86,056,000 as of December 31, 2020[12] - As of June 30, 2021, the group's net current assets were approximately RMB 140,802,000, an increase from RMB 116,924,000 as of December 31, 2020[51] - The group had no borrowings as of June 30, 2021, compared to secured bank borrowings of approximately RMB 1,500,000 as of December 31, 2020[51] Expenses and Costs - Administrative expenses rose by 123.40% compared to the same period in 2020, amounting to RMB (5,853,000) for the six months ended June 30, 2021[25] - The total administrative and employee costs for the period amounted to approximately RMB 10,617,000, up from RMB 7,384,000 in the previous year[50] - The income tax expense for the period was RMB 4,789,000, compared to RMB 3,489,000 in 2020[30] Dividends - The board of directors recommended not to declare any dividend for the six months ended June 30, 2021[7] - The company did not recommend any dividend payment for the period, consistent with the previous year[31] - No dividends were recommended for the six months ended June 30, 2021[53] Employee Information - The group had a total of 85 employees as of June 30, 2021, an increase from 82 employees at the end of 2020[73] - Employee compensation, including salaries and bonuses, amounted to approximately RMB 4,764,000 for the period, consistent with the previous year[73] Corporate Governance - The company adhered to the corporate governance practices as per the GEM Listing Rules, with a noted deviation regarding the separation of the roles of Chairman and CEO[110] - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[112] - As of the report date, the company maintained sufficient public float as per the information available to the board[114] - The company’s board consists of two executive directors and three independent non-executive directors as of the report date[115] Stock Options - The company has a stock option plan in place, granting options to qualified participants[74] - The stock option plan aims to incentivize qualified participants for their contributions to the group's long-term development[91] - The total number of stock options granted during the period was 14,650,000, with a remaining balance of 25,500,000 as of June 30, 2021[105] - The exercise price for the stock options granted in March 2021 was HKD 0.504, with a total of 5,070,000 options granted during this period[105] - The maximum number of shares available for subscription under the stock option plan is 78,087,166 shares, representing 7.85% of the total issued shares as of the interim report date[98] - The maximum number of shares that can be issued to each eligible participant in any 12-month period cannot exceed 1% of the issued shares without shareholder approval[97] Future Plans - The group plans to enhance market promotion capabilities and expand market networks, focusing on a full value chain business model in the local market[52] - The group has established a digital medical service ecosystem, integrating research to rehabilitation[46] Risk Management - The group closely monitors foreign currency risks, with most transactions denominated in RMB, and will hedge as necessary[66] - The board continues to follow a prudent policy to manage cash and maintain strong liquidity to seize future growth opportunities[67] Other Information - There were no significant investments or acquisitions during the period[55][57] - There were no significant subsequent events after June 30, 2021, up to the report date[69] - The company did not engage in any share buybacks, sales, or redemptions during the reporting period[75] - The company has not granted, exercised, canceled, or allowed any other stock options to expire during the reporting period[108]

Financial Performance - For the three months ended March 31, 2021, the group recorded operating revenue of RMB 26,226,000, an increase of 21.58% compared to RMB 21,571,000 for the same period in 2020[6][39] - The group achieved a profit before tax of RMB 15,304,000, which represents a 27.25% increase from RMB 12,027,000 in the same period of 2020[7][20] - Basic and diluted earnings per share for the period were RMB 1.33 cents, up 25.5% from RMB 1.06 cents in the same period of 2020[7][27] - The group’s gross profit for the quarter was RMB 19,671,000, compared to RMB 16,426,000 in the same period of 2020[13] - The group’s total comprehensive income for the period was RMB 13,184,000, compared to RMB 10,573,000 in the same period of 2020[22] - The group’s operating profit for the quarter was RMB 15,318,000, compared to RMB 12,045,000 in the same period of 2020[16] - The net profit for the current period was RMB 13,184,000, up 24.83% from RMB 10,573,000 in the same period last year[41][55] Revenue Sources - The group reported related party revenue of RMB 8,019,000, accounting for approximately 31% of total revenue for the quarter[39] - The company reported related party revenue of RMB 8,019,000, accounting for approximately 31% of total revenue[55] Expenses - Administrative expenses for the quarter were RMB 4,418,000, slightly increasing from RMB 4,400,000 in the same period of 2020[15] - The administrative expenses for the current period were RMB 4,418,000, reflecting a slight increase of 0.41% from RMB 4,400,000 in the previous year[5] Dividend Policy - The board of directors recommended not to declare any dividend for the three months ended March 31, 2021[8] - The company did not recommend any dividend payment for the current quarter, consistent with the previous year[49][57] Corporate Governance - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited first-quarter results for the period ending March 31, 2021[78] - The company emphasizes the importance of corporate governance and has adopted a code of conduct for securities transactions by directors[76] - The board of directors includes two executive directors, Mr. Guo Xia (Chairman) and Dr. Song Xuemei, one non-executive director, Mr. Su Yi, and three independent non-executive directors, Mr. Qiu Rui, Dr. Ni Binhui, and Mr. Zhen Ling[81] - The announcement date is May 13, 2021, indicating the company's ongoing commitment to transparency and governance[81] Strategic Initiatives - The company has established a biobank testing laboratory to support clinical research, particularly for antiviral drug studies[52] - The company is investing in enhancing market promotion capabilities and expanding market networks, focusing on a full-value chain business model in the local market[56] - The company has developed two new business models: RWS-Therapy and D-CRCO, aimed at redefining research-based treatment and commercialization[52] - Future strategies may include the development of new products and technologies to meet evolving market demands[81] - The company aims to leverage strategic partnerships and potential acquisitions to accelerate growth and innovation[81] Shareholder Information - As of March 31, 2021, Winsland Agents Limited holds approximately 35.10% of the company's issued shares, totaling 349,368,873 shares[73] - The company has issued a total of 590,716,637 shares held by major shareholder Guo Xia, representing 59.35% of the total issued shares[67] - The company has granted a total of 250,000 stock options at an exercise price of HKD 0.45 per share, with a one-year lock-up period[69] - Guo Xia is deemed to have interests in 91,915,181 shares held by Bright Excel Assets Limited, a wholly-owned subsidiary of Venturepharm Holdings Inc[68] - The company has a total of 132,851,941 shares held by Guo Xia, which includes 114,701,941 shares directly owned[67] - The company has granted 9,150,000 stock options in 2015 and 9,000,000 stock options in 2021, with varying percentages of exercisability over the years[71] - The company has not reported any other individuals holding interests or short positions in its shares as of March 31, 2021[74] Operational Focus - The company is focused on enhancing its operational efficiency and expanding its market presence in the healthcare sector[81] - Continuous improvement in service delivery and patient care remains a top priority for the organization[81] - User data and customer engagement metrics are expected to be key performance indicators in future reports[81] - The company is committed to maintaining a strong financial position while exploring new market opportunities[81] - The board emphasizes the importance of adapting to market trends and consumer needs in the healthcare industry[81] - The company plans to provide updated performance guidance in upcoming financial disclosures[81]

CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 二零二零年第三季度報告 截至二零二零年九月三十日止九個月 二零二零年第三季度報告 截至二零二零年九月三十日止九個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市之市 場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決 定。GEM 之高風險及其他特色表示 GEM 較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較大之市 場波動風險，同時無法保證在 GEM 買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失 承擔任何責任。 本報告乃遵照聯交所GEM證券上市規則之規定而提供有關中國醫療集團有限公司 ...

Financial Performance - For the six months ended June 30, 2020, the group recorded revenue of approximately RMB 42,023,000, an increase of about 33.78% compared to the same period in 2019[3]. - The group achieved a profit before tax of approximately RMB 25,536,000, representing a growth of approximately 39.40% year-on-year[4]. - Basic earnings per share for the period were approximately RMB 2.22 cents, up about 42.31% from the same period in 2019[5]. - The total comprehensive income for the period was RMB 22,046,000, compared to RMB 15,490,000 for the same period in 2019[15]. - Total revenue for the six months ended June 30, 2020, increased by 33.78% compared to the same period in 2019, with PMS revenue growing approximately 32.83%[22]. - The group reported a basic earnings per share of approximately RMB 22,046,000 for the period, compared to RMB 15,490,000 in the same period of 2019[25]. - The company achieved a pre-tax profit of approximately RMB 25,536,000, compared to RMB 18,319,000 in the same period last year, with a net profit of approximately RMB 22,046,000, up from RMB 15,490,000[33]. Dividends - The board of directors proposed not to declare any dividend for the six months ended June 30, 2020[6]. - No dividends were recommended for the period, consistent with the previous year[29]. - The board of directors did not recommend the distribution of dividends for the six months ended June 30, 2020[38]. Assets and Liabilities - As of June 30, 2020, the group had total current assets of RMB 128,260,000, compared to RMB 106,465,000 as of December 31, 2019[11]. - The group’s net current assets increased to RMB 76,871,000 as of June 30, 2020, compared to RMB 54,743,000 at the end of 2019[11]. - The group’s non-current assets, including property, plant, and equipment, amounted to RMB 4,685,000 as of June 30, 2020[11]. - The group’s total equity increased to RMB 79,026,000 as of June 30, 2020, from RMB 56,980,000 at the end of 2019[11]. - The company’s leverage ratio decreased to approximately 1.13% as of June 30, 2020, down from 1.35% as of December 31, 2019, due to an increase in total assets while total borrowings remained unchanged[35]. - The company has no significant contingent liabilities as of June 30, 2020[45]. Revenue Sources - Revenue from post-listing medical clinical services, clinical research, medical liaison, and medical market services was approximately RMB 41,174,000, accounting for 97.98% of total revenue, up 32.83% from RMB 30,997,000 in the same period last year[33]. - Related party revenue accounted for approximately 28.86% of total revenue, amounting to RMB 12,130,000[22]. Business Development - The group established a biobank testing laboratory to support clinical research, particularly for antiviral drug studies[31]. - The group introduced two new business models: RWS-Therapy and D-CRCO, aimed at redefining research-based treatment and commercialization through digitalization[31]. - The company plans to enhance its market promotion capabilities and expand its market network, focusing on a full value chain business model in the local market[37]. - The group is committed to becoming a comprehensive service provider under an internet framework for medical terminal services[21]. Corporate Governance - The company has complied with the corporate governance practices as per the GEM Listing Rules, with some deviations noted regarding the separation of roles between the chairman and CEO[84]. - The audit committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated results for the period and confirmed compliance with applicable accounting standards[86]. - The board consists of two executive directors, one non-executive director, and three independent non-executive directors as of the agreement date[89]. Employee Information - The company employed 91 staff as of June 30, 2020, down from 153 employees as of December 31, 2019, with total employee compensation during the period amounting to approximately RMB 4,390,000[54]. Shareholder Information - As of June 30, 2020, Guo Xia holds a total of 123,851,941 shares, representing approximately 12.48% of the company's equity[58]. - Winsland Agents Limited, a major shareholder, holds 349,368,873 shares, accounting for 35.19% of the company's equity[61]. - Venturepharm Holdings Inc. owns 149,432,583 shares, which is about 15.05% of the company's equity[61]. - Bright Excel Assets Limited, a subsidiary of Venturepharm Holdings Inc., holds 91,915,181 shares, representing 9.26% of the company's equity[61]. Stock Option Plan - The stock option plan approved in June 2015 has a validity period of 10 years, allowing for the issuance of options until June 29, 2025[65]. - The maximum number of shares available for purchase under the stock option plan is limited to 30% of the issued shares[68]. - The total number of shares available for issuance under the share option plan is 80,667,166 shares, accounting for 8.13% of the total issued shares as of the interim announcement date[70]. - The maximum number of shares that can be issued to each eligible participant within any 12-month period is limited to 1% of the issued shares, unless approved by shareholders[70]. - No performance targets are required to be met before exercising options, unless decided by the board[71]. - The exercise price for options must be at least the higher of the closing price on the grant date or the average closing price over the five trading days prior to the grant date[76]. - The total number of options granted to directors and employees as of June 30, 2015, was 13,490,000, with a remaining balance of 13,430,000 options[81]. - The company has not granted, exercised, canceled, or let expire any other share options during the reporting period[82].

CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (于開曼群島註冊成立之有限公司) (股份代號: 08225) 二零二零年第一季度報告 截至二零二零年三月三十一日止三個月 第一季度報告 截至二零二零年三月三十一日止三個月 香港聯合交易所有限公司（「聯交所」）創業板（「創業板」）特色 創業板之定位,乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市 之市場.有意投資之人士應瞭解投資於該等公司之潛在風險,並應經過審慎周詳之考慮後方 作出投資決定. 由於在創業板上市公司之新興性質所然,在創業板買賣之證券可能會較於聯交所主機板買賣 之證券承受較大之市場波動風險,同時無法保證在創業板買賣之證券會有高流通量之市場. 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告之內容概不負責,對其準確 性或完整性亦不發表任何聲明,並明確表示概不就因本報告全部或任何部份內容而產生或因 倚賴該等內容而引致之任何損失承擔任何責任. 本報告乃遵照聯交所創業板證券上市規則（「創業板上市規則」）之規定而提供有關中國醫 療集團有限公司（「本公司」）及其附屬公司（ ...

Financial Performance - For the nine months ended September 30, 2019, the group recorded revenue of approximately RMB 39,609,000, an increase of about 2.36% compared to the same period in 2018[7]. - The group's profit before tax for the same period was approximately RMB 18,276,000, reflecting a growth of about 2.70% year-over-year[8]. - Basic earnings per share for the nine months ended September 30, 2019, were approximately RMB 1.51 cents, up by about 2.01% from the previous year[9]. - The gross profit for the nine months was approximately RMB 29,843,000, compared to RMB 29,289,000 in the same period last year, indicating a slight increase[13]. - Operating profit for the nine months was approximately RMB 18,340,000, compared to RMB 17,851,000 in the previous year[13]. - The total comprehensive income for the nine months was approximately RMB 15,010,000, compared to RMB 14,714,000 in the same period last year[13]. - Revenue from post-market clinical services, clinical research, medical liaison, and medical market services amounted to RMB 34,478,000, accounting for 87.05% of total revenue[32]. - Administrative expenses increased by 4.14% year-on-year, totaling RMB 11,503,000 for the nine months ended September 30, 2019[24]. - The applicable income tax rate for the period was between 9% and 25%, with some subsidiaries benefiting from a preferential tax rate of 9% due to their location in tax incentive zones[26]. - The group anticipates significant positive impacts on revenue and profit from the approval of ongoing related transactions post-2019[33]. Corporate Governance - The company has not appointed a CEO, with daily operations managed by executive directors and senior management[54]. - The company has complied with the corporate governance code, except for the separation of roles between the chairman and CEO[54]. - Non-executive directors do not have specific terms of appointment but can retire in rotation as per company regulations[54]. - The company aims to encourage attendance of directors at shareholder meetings to enhance transparency and accountability[55]. - The company has made efforts to ensure that independent directors understand shareholder opinions by attending annual general meetings[55]. - The company adopted a code of conduct for securities trading by the board, complying with the GEM Listing Rules[56]. - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements for the nine months ending September 30, 2019, and confirmed compliance with applicable accounting standards[58]. - The board announced delays in publishing the 2018 annual results and report, constituting a violation of GEM Listing Rules[59]. - The company failed to timely publish the Q1 2019 results and report, further violating GEM Listing Rules[59]. Strategic Focus - The group aims to become a comprehensive service provider under an internet framework in the healthcare sector[17]. - The group is focused on providing integrated pharmaceutical services in China, including clinical research and medical marketing[17]. - The group is investing in enhancing marketing capabilities and expanding market networks, focusing on a full-value chain business model in the local market[33]. - There were no significant investments or capital asset plans disclosed beyond what has been announced[38]. - The group closely monitors foreign currency risks and will hedge as necessary, with most transactions denominated in RMB[39]. Shareholding Structure - William Xia GUO holds a total of 712,328,578 shares, representing 71.75% of the company's equity[49]. - Winsland Agents Limited, controlled by William Xia GUO, owns 348,828,873 shares, accounting for 35.14% of the equity[49]. - Venturepharm Holdings Inc. holds 149,432,583 shares, which is 15.05% of the equity[49]. - Bright Excel Assets Limited, fully owned by Venturepharm Holdings Inc., has 91,915,181 shares, representing 9.26% of the equity[49]. - As of September 30, 2019, no other individuals were reported to have a direct or indirect interest of 5% or more in the shares[51].

CHINA HEALTH GROUP INC. 中國醫療集團有限公司 （以「萬全醫療集團」名稱在香港經營業務） (於開曼群島註冊成立之有限公司) (股份代號: 08225) 二零一九年中期報告 截至二零一九年六月三十日止六個月 二零一九年中期報告 截至二零一九年六月三十日止六個月 香港聯合交易所有限公司（「聯交所」）GEM 的特色 GEM 之定位，乃為相比起其他在聯交所上市之公司帶有較高投資風險之公司提供一個上市之市 場。有意投資之人士應瞭解投資於該等公司之潛在風險，並應經過審慎周詳之考慮後方作出投資決 定。GEM 之高風險及其他特色表示 GEM 較適合專業及其他經驗豐富投資者。 由於 GEM 上市公司之新興性質，在 GEM 買賣之證券可能會較於主機板買賣之證券承受較大之市 場波動風險，同時無法保證在 GEM 買賣之證券會有高流通量之市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等內容而引致之任何損失 承擔任何責任。 本報告乃遵照聯交所 GEM 證券上市規則之規定而提供有關中國醫療集團有限公司（「 ...

IC El First China Health Group CHINA HEALTH GROUP INC. 中 國 醫 療 集 團 有 限 公 司 (Carrying on businees in Hong Kong as "萬全醫療集園" ) (以「萬全醫療無劃」名稱在香港嚴重張彥) (Hoorporatiod in the Caynie (andred liability) (Nock Code: 08225) 《 股份代號: 08225) Annual Report 2018 年報 ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2018 CHARACTERISTICS OF THE GROWTH ENTERPRISE MARKET ("GEM") OF THE STOCK EXCHANGE OF HONG KONG LIMITED (THE "STOCK EXCHANGE") GEM has been positioned as a market designed to accommodate companies to which a higher inve ...

Financial Performance - For the three months ended March 31, 2019, the group recorded operating revenue of RMB 16,344,000, an increase of 8.59% compared to RMB 15,051,000 for the same period in 2018[6] - The group reported a profit before tax of RMB 8,349,000 for the three months ended March 31, 2019, which is a 20% increase from RMB 6,958,000 in the same period of 2018[7] - Basic and diluted earnings per share for the three months ended March 31, 2019, were RMB 0.72, up 20% from RMB 0.60 in the same period of 2018[8] - The gross profit for the three months ended March 31, 2019, was RMB 12,451,000, compared to RMB 11,136,000 for the same period in 2018[16] - The net profit attributable to equity holders of the company for the three months ended March 31, 2019, was RMB 7,119,000, compared to RMB 5,914,000 for the same period in 2018[25] - Revenue from post-market medical clinical services, clinical research, medical liaison, and medical market services (PMS) amounted to RMB 15,392,000, accounting for 94.17% of total revenue[63] Expenses and Dividends - Administrative expenses for the three months ended March 31, 2019, were RMB 4,100,000, slightly down from RMB 4,196,000 in the same period of 2018[18] - The company did not recommend any dividend payment for the quarter ended March 31, 2019, consistent with the previous year[60] - Basic earnings per share were calculated based on a profit attributable to ordinary shareholders of approximately RMB 7,119,000, compared to RMB 5,914,000 for the same period in 2018[56] Corporate Governance and Management - The company has complied with the corporate governance code as per the GEM Listing Rules, with only minor deviations regarding the roles of the chairman and CEO[84] - The audit committee, consisting of three independent non-executive directors, is responsible for reviewing the company's financial reports and internal control systems[89] - The company has not appointed a CEO, and daily management is conducted by executive directors and senior management[86] - The company has established a securities trading code for directors, ensuring compliance with trading regulations[85] Shareholding Structure - William Xia Guo holds a total of 712,426,578 shares, representing 71.76% of the company's equity[81] - Winsland Agents Limited, controlled by William Xia Guo, owns 348,068,873 shares, accounting for 35.06% of the total equity[81] - Venturepharm Holdings Inc. holds 149,432,583 shares, which is 15.05% of the company's equity[81] - The company has a total of 123,009,941 shares held by William Xia Guo as a beneficial owner, which includes 10,974,000 shares from stock options[82] - As of March 31, 2019, there were no other individuals holding 5% or more of the company's issued share capital[82] Tax and Financial Policies - The applicable corporate income tax rate for the quarter was between 9% and 25%, with some subsidiaries benefiting from a preferential tax rate of 9% due to their location in tax incentive zones[57] - The company continues to adhere to the revised Hong Kong Financial Reporting Standards without significant changes to its accounting policies[49] Future Outlook and Investments - The company is optimistic about the approval of ongoing related transactions, which are expected to have a significant positive impact on revenue and profit[64] - The company is investing in enhancing marketing capabilities and expanding market networks, focusing on a full value chain business model in the local market[64] - There were no significant investments or capital asset plans disclosed beyond what has been announced by the company[70] Risk Management - The company closely monitors foreign currency risks and will hedge as necessary, with most transactions denominated in RMB[71] Other Information - The company has not disclosed any new product or technology developments in this report[5] - There is no mention of market expansion or acquisitions in the current report[5] - The company has converted all convertible bonds into 77,500,000 shares, eliminating the bondholders' rights to the convertible bonds[79]